HLF-positive B cell acute lymphoblastic leukemia (B-ALL) sits among the most aggressive blood cancers seen in children. The ...

Myeloma delivery constraints are dominated by CAR T infrastructure and onboarding, while bispecifics are more community-feasible after induction; sequencing may favor CAR T first to preserve T-cell ...

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral options. In an interview with Targeted Oncology, Richard Stone, MD, ...

Yatiri used its AI-based proteomics and functional testing platform to identify a biomarker profile for best responders to denfivontinib.

Yatiri Bio, Inc., a leader in AI-driven precision medicine, today announced it has entered into an exclusive global option to license agreement with Oscotec, Inc. to develop and commercialize ...

Patients testing positive for NPM1 MRD pre-alloHCT have significantly increased rates of relapse, reduced overall survival ...

ASH convened a multidisciplinary panel to develop evidence-based guidelines for the treatment of newly diagnosed acute myeloid leukemia in older adults, focusing on balancing treatment efficacy with ...

Glenn Czech, a devoted medical coder and bowler, is remembered for his kindness and faith. Friends and family will gather for his memorial service on March 25th in Sauk Rapids.

A 49-year-old man with a history of acute myeloid leukemia who received an allogeneic bone marrow transplant 2 weeks prior developed a widespread rash. On physical examination, fever of 38.5°C (101.3 ...

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks ...

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today ...